Zacks Research Analysts Raise Earnings Estimates for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) – Equities researchers at Zacks Research upped their Q3 2024 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued on Monday, May 13th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $0.51 per share for the quarter, up […]

Leave a Reply

Your email address will not be published.

Previous post AVITA Medical (NASDAQ:RCEL) Announces Earnings Results, Misses Expectations By $0.47 EPS
Next post AGF Management Ltd. Sells 1,051 Shares of Chemed Co. (NYSE:CHE)